CompareMarketResearchRequest a sample
Home / Healthcare / Companion Diagnostics

Healthcare · Market report

Companion Diagnostics Market Size, Share and Forecast 2026-2036

The global companion diagnostics market is worth USD 7.6 bn in 2026 and is forecast to reach USD 22.6 bn by 2036, growing at a 11.5% CAGR. United States is the largest country market and Next-generation sequencing is the largest by technology segment.

USD 7.6 bnMarket size 2026
USD 22.6 bnForecast 2036
11.5%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global companion diagnostics market is worth USD 7.6 bn in 2026 and is forecast to reach USD 22.6 bn by 2036, growing at a 11.5% CAGR. United States is the largest country market and Next-generation sequencing is the largest by technology segment.

ScopeDiagnostic tests that identify patients who will respond to a specific therapy, including tissue immunohistochemistry, in-situ hybridisation and sequencing-based assays for oncology and other drugs.
IndustryHealthcare
Value 2025USD 6.8 bn
Value 2026USD 7.6 bn
Value 2036USD 22.6 bn
CAGR 2026-203611.5%
Volume 202620.0 million tests
Volume 203653.7 million tests
Average price 2026USD 382 per test
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Companion Diagnostics market size and forecast, 2026-2036

Exhibit 1The global companion diagnostics market is forecast to grow from USD 7.6 bn in 2026 to USD 22.6 bn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 11.5%
Companion Diagnostics market value, 2025 to 2036Market value by year. 2025: USD 6.8 bn; 2026: USD 7.6 bn; 2027: USD 8.5 bn; 2028: USD 9.5 bn; 2029: USD 10.6 bn; 2030: USD 11.8 bn; 2031: USD 13.1 bn; 2032: USD 14.6 bn; 2033: USD 16.3 bn; 2034: USD 18.2 bn; 2035: USD 20.3 bn; 2036: USD 22.6 bn. Compound annual growth rate 2026 to 2036: 11.5%.20257.6 bn202613.1 bn203122.6 bn203611.5% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 7.6 bn
2027USD 8.5 bn
2028USD 9.5 bn
2029USD 10.6 bn
2030USD 11.8 bn
2031USD 13.1 bn
2032USD 14.6 bn
2033USD 16.3 bn
2034USD 18.2 bn
2035USD 20.3 bn
2036USD 22.6 bn

Companion Diagnostics market segmentation

By technology

Exhibit 2Next-generation sequencing is the largest segment by technology, with 36.0% of 2026 revenueEstimated share of 2026 global revenue, by technology
Companion Diagnostics market share by technology, 2026Share of 2026 revenue by technology. Next-generation sequencing: 36.0%; Immunohistochemistry: 28.0%; Polymerase chain reaction: 20.0%; In situ hybridisation: 12.0%; Other methods: 4.0%.Next-generation sequencing36.0%Immunohistochemistry28.0%Polymerase chain reaction20.0%In situ hybridisation12.0%Other methods4.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Next-generation sequencing36.0%48.5%USD 2.7 bn14.9%
Immunohistochemistry28.0%20.1%USD 2.1 bn7.9%
Polymerase chain reaction20.0%18.9%USD 1.5 bn10.9%
In situ hybridisation12.0%9.9%USD 914 mn9.4%
Other methods4.0%2.6%USD 305 mn6.9%

By indication

Exhibit 3Lung cancer adds the most revenue by indication, growing from USD 2.1 bn in 2026 to USD 6.0 bn by 2036Estimated revenue in USD by indication, 2026 and 2036 forecast
Companion Diagnostics market by indication, 2026 and 2036Revenue by indication in 2026 and 2036. Lung cancer: USD 2.1 bn in 2026, USD 6.0 bn in 2036, change +183%; Breast cancer: USD 1.8 bn in 2026, USD 4.5 bn in 2036, change +147%; Prostate and ovarian cancer: USD 1.1 bn in 2026, USD 3.9 bn in 2036, change +270%; Other cancers: USD 914 mn in 2026, USD 2.8 bn in 2036, change +210%; Colorectal cancer: USD 914 mn in 2026, USD 2.7 bn in 2036, change +196%; Non-oncology: USD 762 mn in 2026, USD 2.6 bn in 2036, change +239%.20262036 forecastChangeLung cancer+183%2.1 bn6.0 bnBreast cancer+147%1.8 bn4.5 bnProstate and ovarian cancer+270%1.1 bn3.9 bnOther cancers+210%914 mn2.8 bnColorectal cancer+196%914 mn2.7 bnNon-oncology+239%762 mn2.6 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Lung cancer28.0%26.7%USD 2.1 bn11.0%
Breast cancer24.0%20.0%USD 1.8 bn9.5%
Colorectal cancer12.0%12.0%USD 914 mn11.5%
Prostate and ovarian cancer14.0%17.4%USD 1.1 bn14.0%
Other cancers12.0%12.5%USD 914 mn12.0%
Non-oncology10.0%11.4%USD 762 mn13.0%

By biomarker type

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Protein (IHC)34.0%30.0%USD 2.6 bn10.1%
Genetic mutation40.0%42.0%USD 3.0 bn12.1%
Gene expression14.0%14.0%USD 1.1 bn11.5%
Others markers12.0%14.0%USD 914 mn13.2%

By platform

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Immunohistochemistry34.0%29.0%USD 2.6 bn9.7%
PCR and qPCR24.0%22.0%USD 1.8 bn10.5%
Next-generation sequencing30.0%38.0%USD 2.3 bn14.2%
In situ hybridization12.0%11.0%USD 914 mn10.5%

By sample type

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Solid tumor tissue60.0%54.0%USD 4.6 bn10.3%
Blood and liquid biopsy28.0%34.0%USD 2.1 bn13.7%
Cytology and others12.0%12.0%USD 914 mn11.5%

Top 25 countries for companion diagnostics by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 87.5% of 2026 revenue and the 25 countries below together hold 96.3%.

Exhibit 4United States is the largest country market at USD 3.5 bn in 2026, and the three largest countries hold 62.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Companion Diagnostics market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 3.5 bn, 46.0%; China: USD 685 mn, 9.0%; Germany: USD 533 mn, 7.0%; Japan: USD 533 mn, 7.0%; France: USD 305 mn, 4.0%; United Kingdom: USD 305 mn, 4.0%; Italy: USD 228 mn, 3.0%; Spain: USD 190 mn, 2.5%; South Korea: USD 190 mn, 2.5%; Canada: USD 190 mn, 2.5%.United States3.5 bn 46.0%China685 mn 9.0%Germany533 mn 7.0%Japan533 mn 7.0%France305 mn 4.0%United Kingdom305 mn 4.0%Italy228 mn 3.0%Spain190 mn 2.5%South Korea190 mn 2.5%Canada190 mn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 3.5 bn46.0%USD 9.7 bn10.7%
2ChinaUSD 685 mn9.0%USD 3.1 bn16.2%
3GermanyUSD 533 mn7.0%USD 1.5 bn10.7%
4JapanUSD 533 mn7.0%USD 1.5 bn11.2%
5FranceUSD 305 mn4.0%USD 814 mn10.3%
6United KingdomUSD 305 mn4.0%USD 837 mn10.6%
7ItalyUSD 228 mn3.0%USD 611 mn10.3%
8SpainUSD 190 mn2.5%USD 520 mn10.6%
9South KoreaUSD 190 mn2.5%USD 656 mn13.2%
10CanadaUSD 190 mn2.5%USD 498 mn10.1%
11SwitzerlandUSD 98 mn1.3%USD 292 mn11.5%
12NetherlandsUSD 97 mn1.3%USD 292 mn11.6%
13AustraliaUSD 90 mn1.2%USD 267 mn11.5%
14BelgiumUSD 76 mn1.0%USD 228 mn11.6%
15SwedenUSD 65 mn0.8%USD 192 mn11.5%
16DenmarkUSD 47 mn0.6%USD 140 mn11.5%
17BrazilUSD 43 mn0.6%USD 145 mn12.8%
18TaiwanUSD 34 mn0.5%USD 115 mn12.9%
19IsraelUSD 27 mn0.3%USD 79 mn11.5%
20AustriaUSD 23 mn0.3%USD 68 mn11.5%
21SingaporeUSD 19 mn0.2%USD 63 mn12.8%
22PolandUSD 16 mn0.2%USD 54 mn13.0%
23IndiaUSD 14 mn0.2%USD 48 mn13.2%
24MexicoUSD 14 mn0.2%USD 48 mn13.2%
25Saudi ArabiaUSD 11 mn0.1%USD 36 mn13.0%
Rest of worldUSD 278 mn3.6%USD 828 mn11.5%
Exhibit 5United States and China account for 57% of the USD 15.0 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Companion Diagnostics market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 7.6 bn. United States: +USD 6.2 bn; China: +USD 2.4 bn; Japan: +USD 1.0 bn; Germany: +USD 937 mn; United Kingdom: +USD 532 mn; 20 other countries: +USD 3.4 bn; Rest of world: +USD 550 mn. Market value 2036: USD 22.6 bn.Market value 20267.6 bnUnited States+6.2 bnChina+2.4 bnJapan+1.0 bnGermany+937 mnUnited Kingdom+532 mn20 other countries+3.4 bnRest of world+550 mnMarket value 203622.6 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Roche Diagnostics
  • Agilent Technologies
  • Thermo Fisher Scientific
  • Qiagen
  • Illumina
  • Abbott

Group 2: Regional and specialist players

  • Guardant Health
  • Myriad Genetics
  • Labcorp
  • Quest Diagnostics
  • Foundation Medicine
  • Tempus AI
  • Caris Life Sciences
  • Almac Diagnostic Services
  • Leica Biosystems

Group 3: Emerging and niche players

  • Biocartis
  • Pillar Biosciences
  • Burning Rock Biotech
  • Personalis
  • Sysmex

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the companion diagnostics market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 11.5% is calculated from the resulting values.

The market is divided by technology, by indication, by biomarker type, by platform, by sample type. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the companion diagnostics market?

The global companion diagnostics market is estimated at USD 6.8 bn in 2025 and USD 7.6 bn in 2026.

How fast will the companion diagnostics market grow?

It is forecast to reach USD 22.6 bn by 2036, a compound annual growth rate of 11.5% from 2026, an increase of USD 15.0 bn.

Which country is the largest market for companion diagnostics?

United States is the largest market by revenue at USD 3.5 bn in 2026, 46.0% of the global total. The three largest countries together hold 62.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 16.2% a year from 2026 to 2036.

Which companion diagnostics segment is largest?

In the by technology split, Next-generation sequencing is the largest segment with 36.0% of 2026 revenue.

Who are the leading companion diagnostics companies?

Global leaders include Roche Diagnostics, Agilent Technologies, Thermo Fisher Scientific, Qiagen.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Colorimetric Fructosamine Assay Kit Comparator Sourcing →

All Healthcare markets →

Request a sample